Association between the presence of autoantibodies against adrenoreceptors and hypertensive disorders in pregnancy: a pilot study

Agata Szpera-Goździewicz¹, Tomasz Goździewicz², Przemysław Wirstlein³, Ewa Wender-Ożegowska¹, Grzegorz H. Bręborowicz¹

¹ Department and Division of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznań, Poland
² Division of Gynecology, Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznań, Poland
³ Division of Reproduction, Department of Obstetrics, Gynecology and Gynecologic Oncology, Poznan University of Medical Sciences, Poznań, Poland

Introduction
There are numerous factors considered to cause pregnancy-related hypertension, including genetic, immunological, environmental, and behavioral ones, as well as those related to endothelial dysfunction.

The immune system can identify foreign antigens and eliminate them from the human body. In the case of immune control mechanism failure, the immune system may be directed at a self-antigen. More recent data have shown characteristic molecular targets of autoantibodies common in patients with preeclampsia and essential hypertension, potentially explaining how elevated autoantibody titers might contribute to hypertension. Wallukat and Schimke¹ demonstrated the presence of autoantibodies against α₁-, β₁-, and β₂-adrenoreceptors (anti–α₁-ARs, anti–β₁-ARs, and anti–β₂-ARs, respectively) that bind to the second extracellular loop of receptors and are highly prevalent in the serum of hypertensive patients.

It is well known that neoangiogenesis is a multistep process closely associated with endothelial cell migration and proliferation.² Stimulation of α-ARs localized in endothelial cells leads to negative regulation of angiogenesis, whereas β-ARs stimulate neoangiogenesis. Moreover, in hypertension characterized by the impairment of angiogenesis, the α₁-AR tone is higher than that of β₂-ARs.³ Taking these facts into consideration, we hypothesized that abnormal stimulation of these receptors by autoantibodies might lead to abnormal angiogenesis, which is crucial for placental development.

To verify this hypothesis, we evaluated the correlation between the titers of these autoantibodies and ultrasound Doppler flow measurements that reflect placental insufficiency. Moreover, the aim of our study was to investigate the differences in anti–α₁-AR, anti–β₁-AR, and anti–β₂-AR titers between pregnant patients with chronic hypertension (CH), gestational hypertension (GH), and preeclampsia and healthy pregnant women. Finally, we investigated the relationship between autoantibody titers and the severity of preeclampsia (based on systolic and diastolic blood pressure values and urinary protein excretion).

Patients and methods
The study was performed with approval from the Bioethics Committee of the Poznan University of Medical Sciences, Poznań, Poland (No. 563/13). Each woman received detailed information about the project and provided informed consent before participating in the study.

A case control study was conducted in the Department of Perinatology and Gynecology of the Poznan University of Medical Sciences between November 2014 and March 2016. We analyzed the following groups of women—pregnant patients with preeclampsia (n = 16), those with CH (n = 13), and those with GH (n = 17). The control group consisted of 17 healthy, normotensive pregnant women. The compared groups were matched for the mother’s age, parity, prepregnancy body mass index, and gestational age at the time of recruitment into the study and blood collection.

Hypertensive disorders were defined in accordance with the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy classification.⁴ The exclusion criteria for the control and study groups were systemic diseases related to endothelial dysfunction (eg, kidney diseases, diabetes mellitus, atherosclerotic diseases, inflammatory/infectious...
The clinical characteristics of the control and study groups are shown in Table 1. There were no significant differences between these groups in terms of patient age, parity, prepregnancy body mass index, and gestational age at the time of recruitment to the study and blood collection. The mean (SD) urinary protein excretion in the control and study groups are shown in Table 1. The mean (SD) urinary protein excretion in patients with preeclampsia was 2.6 (2.15) g/24 h.

The median of anti-α₁-AR, anti-β₂-AR, and anti-β₁-AR titers in each group of women are presented in Table 1. Interestingly, there were only two patients who were positive for anti-α₁-ARs. The first was a 28-year-old patient in the 39th week of an uncomplicated pregnancy and the other was a 22-year-old woman with CH in the 26th week of gestation. There were no significant differences in anti-α₁-AR, anti-β₂-AR, and anti-β₁-AR titers between the study and control groups (Table 1). Moreover, in the CH group, we found a negative correlation between anti-β₁-AR titers and maximum systolic blood pressure ($r = -0.62; P = 0.02$). There were no significant correlations between autoantibody titers and the severity of preeclampsia. We did not observe a correlation between gestational age at sampling and autoantibodies titers in any of the groups.

In 73% of patients with preeclampsia, placental insufficiency was detected by ultrasound examination, whereas it was detected in only 33% and 8% of women with CH and GH, respectively. Furthermore, our analysis did not reveal any correlations between anti-α₁-AR and anti-β₂-AR titers and ultrasonographic features of placental insufficiency in any of the groups.

**Discussion** Based on our hypothesis, we expected that the titers of adrenoreceptor autoantibodies would be significantly different in the serum of pregnant women with hypertensive disorders than in that of healthy pregnant controls. The exact pathophysiology and etiology of hypertensive disorders in pregnant women remain elusive, but there is growing evidence for the involvement of the immune system in these processes. Dysfunction in immunological mechanisms may impair spiral artery invasion, leading to placental insufficiency and elevated blood pressure. The α₁-ARs are primarily expressed on vascular smooth muscle cells and proximal renal tubules, and their activation causing elevated blood pressure. In 1994, anti-α₁-ARs were detected for the first time in patients with malignant hypertension and soon after were reported in patients with primary hypertension. The β₂-ARs are localized mainly in cardiac tissue, and their stimulation is followed by an increase in cardiac output, which is the main blood pressure regulator. It is widely accepted that β₂-ARs are localized on endothelial cells and regulate vasomotor tone and cause endothelial nitric oxide activation, which is followed by vasorelaxation. Therefore, we hypothesized that there is a relationship between the presence of these autoantibodies and the development of different types of hypertensive disorders in pregnancy.

Only one published study examined the association between the presence of autoantibodies against adrenoreceptors and severe preeclampsia. In contrast to our results, the authors showed that anti-α₁-ARs, anti-β₁-ARs, and anti-β₂-ARS titers were significantly increased in patients with severe preeclampsia and concluded that these autoantibodies may be involved in the pathogenesis of this disease. Interestingly, in our study, there were only 2 patients with positive anti-α₁-AR titers, and these patients differed in health status. This finding may suggest that these autoantibodies occur incidentally, independently from any underlying disease.

Importantly, in our study, we included women with preeclampsia as well as those with CH and GH, which is a novel aspect of our investigation. There are few similar risk factors that contribute to the development of GH and preeclampsia,
The study was funded by...

TABLE 1 Clinical characteristics and autoantibody titeres of the study and control groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Gestational hypertension (n = 17)</th>
<th>Preeclampsia (n = 16)</th>
<th>Chronic hypertension (n = 13)</th>
<th>Control group (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean (SD)</td>
<td>29 (3)</td>
<td>30 (7)</td>
<td>32 (5)</td>
<td>32 (4)</td>
</tr>
<tr>
<td>Gestational age at recruitment, wk, median (min–max)</td>
<td>38 (20–41)</td>
<td>32 (26–40)</td>
<td>34 (22–40)</td>
<td>38 (21–41)</td>
</tr>
<tr>
<td>Parity, median (min–max)</td>
<td>1 (1–3)</td>
<td>1 (1–3)</td>
<td>2 (1–5)</td>
<td>2 (1–5)</td>
</tr>
<tr>
<td>Prepregnancy BMI, kg/m², mean (SD)</td>
<td>28.3 (4.6)</td>
<td>28.0 (4.3)</td>
<td>28.4 (9.6)</td>
<td>25.1 (4.6)</td>
</tr>
<tr>
<td>Mean SBP, mm Hg, mean (SD)</td>
<td>134 (15)</td>
<td>139 (12)</td>
<td>131 (11)</td>
<td>111 (9)</td>
</tr>
<tr>
<td>Mean DBP, mm Hg, mean (SD)</td>
<td>84 (10)</td>
<td>90 (8)</td>
<td>83 (9)</td>
<td>70 (7)</td>
</tr>
<tr>
<td>Maximum SBP, mm Hg, mean (SD)</td>
<td>160 (23)</td>
<td>169 (20)</td>
<td>164 (23)</td>
<td>119 (11)</td>
</tr>
<tr>
<td>Maximum DBP, mm Hg, mean (SD)</td>
<td>106 (17)</td>
<td>109 (11)</td>
<td>113 (19)</td>
<td>78 (12)</td>
</tr>
<tr>
<td>Anti–α₁-ARs, n (%)</td>
<td>0</td>
<td>0</td>
<td>1 (7.7)</td>
<td>1 (5.9)</td>
</tr>
<tr>
<td>Anti–β₁-ARs, ng/ml, median (IQR)</td>
<td>1.4 (1.07–1.68)</td>
<td>1.13 (0.74–3.45)</td>
<td>1.51 (1.07–1.70)</td>
<td>1.27 (0.88–1.53)</td>
</tr>
<tr>
<td>Anti–β₂-ARs, U/ml, median (IQR)</td>
<td>4.39 (2.94–6.65)</td>
<td>3.6 (2.83–4.75)</td>
<td>3.36 (1.99–4.54)</td>
<td>5.25 (3.16–6.57)</td>
</tr>
</tbody>
</table>

Abbreviations: α₁-ARs, autoantibodies against α₁-adrenoreceptors; β₁-ARs, autoantibodies against β₁-adrenoreceptors; β₂-ARs, autoantibodies against β₂-adrenoreceptors; BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure

which may suggest that they are congenital diseases.11 Furthermore, patients with severe GH have an independently increased perinatal risk and even worse outcomes than those with mild preeclampsia.11,12 These factors suggest that patients with CH and GH should be included in studies examining hypertensive disorders in pregnancy.

We found a significant negative correlation between anti–β₂-AR titers and maximum systolic blood pressure in the CH group. It is well known that agonist binding of these autoantibodies to β₂-ARs causes receptor activation followed by vasorelaxation.3 Our results suggest that these autoantibodies may be protective in patients with CH; moreover, in patients with higher levels of these autoantibodies blood pressure may be lower.

Our analysis did not reveal any correlation between anti–α₁-AR or anti–β₁-AR titers and ultrasonographic features of placental insufficiency. Unfortunately, our hypothesis was not confirmed, which may indicate that the abnormal stimulation of these receptors by autoantibodies is not related to the pathogenesis of hypertensive disorders in pregnancy and with placental insufficiency.

Based on our findings, we assume that anti–α₁-ARs, anti–β₁-ARs, and anti–β₂-ARs are unlikely to be involved in the pathogenesis of hypertensive disorders in pregnant women. In pregnant patients with CH, anti–β₂-ARs may play a protective role. However, to date, there have been few studies on this topic, so further research is needed to investigate these findings and to expand the knowledge about the etiopathogenesis of hypertension in pregnancy.

Acknowledgments The study was funded by the Poznan University of Medical Sciences, Poznań, Poland (grant no., 502-14-0218 346-50 637; to AS-G).

REFERENCES

RESEARCH LETTER Autoantibodies and hypertension in pregnancy